Congress
$1,001–$15,000
Traded Sep 24 · disclosed 13 days later
Since the trade
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
BIIB · NASDAQ · Biotechnology
Biogen (BIIB) · oqro.io/stocks/BIIB · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Baskets of the companies that insiders, members of Congress or funds recently reported buying, each held under a written rule.
No open-market purchase by an insider of Biogen was filed in the last 90 days. The latest on record was on Feb 18, 2026.
Since 2004, Biogen insiders reported 34 open-market purchases and 1,393 sales on Forms 4 and 5, with purchases in 10 different years, most recently 2026.
No open-market sale by an insider of Biogen (BIIB) was filed with the SEC in the last 90 days.
Yes. Members of Congress disclosed 9 trades in Biogen (BIIB) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Rep. Maria Elvira Salazar (FL27), Rep. Kevin Hern (OK01), Sen. Alan Armstrong and 1 other member.
Biogen's next results are expected on Feb 4, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$251.41+0.62 (+0.25%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
+48.9% (+$82.58) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $168.83 on Nov 18, 2025 to $251.41 on Nov 18, 2026 (+48.9%). Disclosed in this range: 5 insider trades, 0 pre-arranged insider sales, 9 Congress trades, and 40 13F position changes for 3 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biotechnology company based in Cambridge, Massachusetts.
Last 12 months
+48.9%
Market value
$37.2B
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 5.45M shares sold short (3.7% of shares outstanding), −0.9% vs the previous count, 4.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$2.8B
+10.6% vs the same quarter a year earlier
Free cash flow, last 12 months
$2.07B
This quarter $600M, a year earlier $1.23B
Net debt
$5.99B
Debt $7.29B, cash $1.3B, at Sep 30, 2026
Net income, last 12 months
$348M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 28, 2026.
Revenue, fiscal 2025
$9.89B
+2.2% vs the year before
Net income, fiscal 2025
$1.29B
As reported in the annual filing
Shares outstanding
148M
As of Oct 26, 2026
Congress
Traded Sep 24 · disclosed 13 days later
Since the trade
Congress
Traded Aug 18 · disclosed 14 days laterSits on House Ways and Means, Health
Since the trade +18.3% · S&P 500 −4.8% · to Nov 18
3 different filers disclosed BIIB within 90 days.
Fund moves
16 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
7 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
52 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Against the S&P 500 over the year
Since Nov 14, 2025, BIIB is up 49.7% and the index fund is up 9.0%: 41 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much BIIB moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Insiders of Biogen reported 34 open-market purchases and 1,393 sales since 2004; purchases in 10 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $5851×1 trade | $905K4×4 trades |
| 2025 | $152K1×1 trade | $2.16M4×4 trades |
| 2024 | $101K1×1 trade | $463K7×7 trades |
| 2023 | — | $1.15M6×6 trades |
| 2022 | — | $3.24M2×2 trades |
| 2021 | $240K1×1 trade | $4.83M3×3 trades |
| 2020 | $748K1×1 trade | $1.24M3×3 trades |
| 2019 | $48.8M7×7 trades | $2.32M2×2 trades |
| 2018 | $13M1×1 trade | $3.22M6×6 trades |
| 2017 | $31.1M7×7 trades | $12.1M8×8 trades |
| 2016 | — | $11.5M20×20 trades |
| 2015 | $89.1M4×4 trades | $29.5M45×45 trades |
| 2014 | — | $44.6M68×68 trades |
| 2013 | — | $88.7M90×90 trades |
| 2012 | — | $43.7M55×55 trades |
| 2011 | — | $33.4M70×70 trades |
| 2010 | $80K10×10 trades | $34.8M34×34 trades |
| 2009 | — | $12.8M23×23 trades |
| 2008 | — | $88.5M633×633 trades |
| 2007 | — | $89.5M131×131 trades |
| 2006 | — | $47.1M120×120 trades |
| 2005 | — | $3.11M9×9 trades |
| 2004 | — | $10.6M50×50 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the public record for Biogen over the 12 months to Nov 18, 2026: 1 FDA record, 4 executive contributions and 22 clinical trials.
FMR LLC
Schedule 13G: passive · filed Aug 6, 2026 · 18.3M shares
Vanguard Capital Management
Schedule 13G: passive · filed Apr 29, 2026 · 11M shares
STATE STREET CORPORATION
Schedule 13G: passive · filed Nov 10, 2026 · 7.57M shares
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Granting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
Notice · Federal Trade Commission
Advisory Committee; Peripheral and Central Nervous System Drugs Advisory Committee; Termination and Reestablishment
Notice · Food and Drug Administration
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
28 certified in FY2026 Q3, vs 35 a year earlier. 28 positions in total, median offered wage $137K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Last results
Oct 28, 2026
Within the 30 days after it, until Nov 27, 2026
Next results, expected
Feb 4, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
79%
19 of 24 insider purchases since 2014 came within 30 days after a results announcement
From Biogen's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Biogen's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
17 active phase 3 trials and 5 active phase 2 trials led by this company, mostly in lupus erythematosus, systemic, subacute cutaneous lupus erythematosus, antibody-mediated rejection. The ones with the nearest registered primary completion date still ahead:
4 trials have a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
2 approvals or clearances and 0 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Short sale volume: 61.0% of the volume reported to FINRA over the last 20 trading days was marked short, above its 1-year average of 58.6%. FINRA daily files, to Nov 18, 2026.
Fails to deliver: 42K shares (about $9.66M) were not delivered on time for settlement on Oct 19, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.